BiotechTube

ERAS-007 + ERAS-601

Phase 1/2Active
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced or Metastatic Solid Tumors

Conditions

Advanced or Metastatic Solid Tumors

Trial Timeline

May 7, 2021 → Nov 1, 2025

NCT ID
NCT04866134

About ERAS-007 + ERAS-601

ERAS-007 + ERAS-601 is a phase 1/2 stage product being developed by Erasca for Advanced or Metastatic Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT04866134. Target conditions include Advanced or Metastatic Solid Tumors.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04866134Phase 1/2Active

Competing Products

20 competing products in Advanced or Metastatic Solid Tumors

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Erasca

Naporafenib + Dacarbazine + Temozolomide + TrametinibPhase 3
74
ERAS-007 + Encorafenib + Cetuximab + PalbociclibPhase 1/2
38
ERAS-007 + ERAS-601 + GilteritinibPhase 1/2
38
ERAS-601 + Cetuximab + PembrolizumabPhase 1
30
ERAS-0015 + ERAS-0015 in combinationPhase 1
30